Ropes & Gray advised Novo Nordisk in a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic diseases. Novo Nordisk will receive an exclusive worldwide license to use NanoVation’s long-circulating lipid nanoparticle technology for RNA delivery targeting cells outside the liver. The partnership was announced on September 18.
Under the agreement, Novo Nordisk and NanoVation will collaborate to develop base-editing therapies for certain rare genetic diseases and cardiometabolic and rare diseases. NanoVation will receive research funding and is eligible to receive up to $600 million in up-front cash and potential milestone payments, as well as tiered royalties on future product sales.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associates Mallory Ursul and Ian Nilsen.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.